CompBrief BY VELARION

Companies Cano Health

Cano Health CEO salary & total pay, FY2022: $4.3M

Cano Health (CANO) CEO salary, fiscal 2022: Marlow Hernandez was paid a salary of $350,000 and $4,320,007 in total compensation. Free brief. Every figure links to the company’s own filing.

Cano Health no longer files a proxy statement; its last pay data is FY2022.

All products and prices

Marlow Hernandez's complete compensation dossier

A PDF and a CSV sent to your email: Marlow Hernandez's pay in every fiscal year Cano Health reported it, line by line, with Marlow Hernandez's equity grants and Cano Health's disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$4,320,007CEO Marlow Hernandez · source
Say-on-pay support26.77%Latest vote · source
CEO vs. named peers17th pct.Of 16 peer CEOs
CEO pay ratio114:1To the median employee

CEO pay, last three years

  • $1,052,808FY2020
  • $31,685,996FY2021
  • $4,320,007FY2022

CEO total pay was $4,320,007 in fiscal 2022, down from $31,685,996 in fiscal 2021.

FY2022: salary $350,000 · bonus $0 · stock awards $3,421,127 · option awards $539,999

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Cano Health in fiscal 2022?
As disclosed, Marlow Hernandez (Chief Executive Officer) was the highest-paid executive at Cano Health in fiscal 2022, with total compensation of $4,320,007.
How does Cano Health's chief executive pay compare to its disclosed peer group?
As disclosed, Marlow Hernandez's total compensation ranked at the 17th percentile of Cano Health's disclosed peer group.
What is Cano Health's CEO-to-median employee pay ratio?
As disclosed, Cano Health's CEO-to-median employee pay ratio was 114:1.
How did shareholders vote on Cano Health's executive compensation?
As disclosed, 26.77% of shareholders supported Cano Health's executive compensation in the latest say-on-pay vote.
How much does Cano Health spend in total on board compensation for fiscal 2022?
As disclosed, Cano Health reported total board compensation of $3,084,594 for fiscal 2022.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Marlow Hernandez$350,000$0$3,421,127$539,999$0$0$8,881$4,320,007
Chief Executive Officer
Robert Camerlinck468,62303,187,38244,798002,8823,703,685
Chief Operating Officer
Brian Koppy325,0000953,723142,322008,9001,429,945
Chief Financial Officer
Richard Aguilar300,0000919,032144,8020001,363,834
Chief Clinical Officer
David Armstrong235,0000687,981108,601008,9691,040,551
Chief Compliance Officer and General Counsel

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2022 totalFY2021 totalFY2020 totalΔ FY2021→2022
Marlow Hernandez$4,320,007$31,685,996$1,052,808↓ −27,365,989
Robert Camerlinck3,703,685———
Brian Koppy1,429,94510,518,124—↓ −9,088,179
Richard Aguilar1,363,83410,076,489350,000↓ −8,712,655
David Armstrong1,040,5517,714,038325,880↓ −6,673,487

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation philosophy is focused on pay-for-performance. In this regard, we link a significant portion of each NEO's target TDC to the achievement of specified performance goals or appreciation in the market price of our common stock.

CEO STI target (% of salary)50%
CEO LTI target (% of salary)—
Independent consultantFW Cook
Clawback policytrue
Anti-hedgingTrue
Anti-pledgingTrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2022

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Marlow HernandezRSU2022-03-15——567,351—$3,421,127
Robert CamerlinckOPTION2022-03-15——11,546—44,798
Richard AguilarRSU2022-03-15——152,410—919,032
Richard AguilarOPTION2022-03-15——37,320—144,802
Marlow HernandezOPTION2022-03-15——139,175—539,999
Robert CamerlinckRSU2022-08-10——250,000—1,185,000
David ArmstrongRSU2022-03-15——114,093—687,981
David ArmstrongOPTION2022-03-15——27,990—108,601
Robert CamerlinckRSU2022-03-15——332,070—2,002,382
Brian KoppyRSU2022-03-15——158,163—953,723
Brian KoppyOPTION2022-03-15——36,681—142,322

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Marlow Hernandez$3,421,127$0$539,9990.0%
Robert Camerlinck3,187,382044,7980.0%
Richard Aguilar919,0320144,8020.0%
David Armstrong687,9810108,6010.0%
Brian Koppy953,7230142,3220.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2022

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Richard AguilarOption—600,70014.75—
Richard AguilarRSU—150,000—205,500
Richard AguilarRSU—214,000—293,180
Richard AguilarOption—37,3206.03—
Richard AguilarRSU—85,821—117,575
Brian KoppyRSU—280,479—384,256
Brian KoppyOption—400,00014.75—
Brian KoppyRSU—142,500—195,225
Brian KoppyOption—36,6816.03—
Brian KoppyRSU—90,640—124,177
David ArmstrongOption—600,70014.75—
David ArmstrongRSU—37,500—51,375
David ArmstrongRSU—214,000—293,180
David ArmstrongOption—27,9906.03—
David ArmstrongRSU—62,737—85,950
HernandezOption—2,820,00014.75—
HernandezRSU—1,004,625—1,376,336
HernandezOption—139,1756.03—
HernandezRSU—312,210—427,728
HernandezRSU—1,004,625—1,376,336
HernandezOption—139,1756.03—
HernandezRSU—312,210—427,728
Richard AguilarRSU—150,000—205,500
Richard AguilarRSU—214,000—293,180
Richard AguilarOption—37,3206.03—
Richard AguilarRSU—85,821—117,575
Robert CamerlinckOption—600,70014.75—
Robert CamerlinckRSU—214,000—293,180
Robert CamerlinckOption—11,5466.03—
Robert CamerlinckRSU—23,369—32,016
Robert CamerlinckRSU—250,000—342,500
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Solomon D. TrujilloIndependent · Lead Independent Director · Nominating and Corporate Governance Committee · Compensation$83,194$362,981$0—$0$446,175
Elliot CooperstoneNot independent48,937327,9800—0376,917
Jacqueline GuichelaarIndependent · Audit · Nominating and Corporate Governance Committee48,937327,9800—0376,917
Dr. Lewis GoldNot independent48,937327,9800—0376,917
Angel MoralesIndependent · Audit (Chair) · Compensation48,937327,9800—0376,917
Barry S. SternlichtNot independent48,937327,9800—0376,917
Kim RiveraIndependent · Audit · Nominating and Corporate Governance Committee (Chair)48,937327,9800—0376,917
Dr. Alan MuneyIndependent · Audit · Compensation (Chair)48,937327,9800—0376,917
Dr. Marlow HernandezEmployee director · Board Chair000—00

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$200,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guideline5x annual cash retainer

Total cost of the board

ComponentFY2022
Cash retainers and fees$425,753
Equity awards (grant-date value)$2,658,841
All other compensation$0
Total cost of the board$3,084,594

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Cano Health as a peer

Companies that benchmark against CANO

No companies currently name CANO as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Disclosed peer group — fiscal year 2022

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Apollo Medical Holdings2025Brandon Sim$850,000$11,999,980$0$2,059,125$14,930,231
2Mednax (MD)2025Mark Ordan970,0148,456,02402,700,00014,140,217
3The Ensign Group2025Barry Port549,2642,912,355010,317,24713,804,700
4Addus HomeCare2025R. Dirk Allison1,076,9239,767,87001,320,00012,190,449
5RadNet2025Howard Berger3,000,0008,999,9660012,087,934
6Teladoc Health2025Charles Divita, III800,0009,699,9960584,00011,202,996
7Encompass Health2025Mark Tarr1,100,0005,285,3811,165,3762,581,52510,297,258
8Acadia Healthcare2025Christopher Hunter1,061,0005,712,01201,135,2707,909,463
9Surgery Partners2025J. Eric Evans1,050,0005,000,000006,083,862
10U.S. Physical Therapy2025Christopher Reading1,003,1251,955,25001,506,3754,468,314
11Cano Health2022Marlow Hernandez350,0003,421,127539,99904,320,007
12National HealthCare2025Stephen Flatt577,000505,215300,4811,280,0002,685,370
13CorVel2026Michael Combs679,3270101,716498,8091,285,043
—1Life Healthcare——————not in coverage universe
—Amedisys——————not in coverage universe
—Oak Street Health——————not in coverage universe
—LHC Group——————not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Cano Health0%PSU 80 · Options 20Yes — Relative TSRFW Cook
1Life Healthcarenot disclosednot disclosednot disclosednot disclosed
Acadia Healthcare85.6%PSU 50 · RSU 50NoWTW
Addus HomeCarenot disclosedRestricted Stock 100not disclosedFW Cook
Amedisysnot disclosednot disclosednot disclosednot disclosed
Apollo Medical Holdings193.8%PSU 67 · RSU 33NoPearl Meyer
CorVelCEO: 75%, EVP Risk: 61%, CIO: 49%, VP Accounting: 28%%not disclosedNonot disclosed
Encompass Health173.8%PSU 60 · RSU 20 · Options 20NoPay Governance
LHC Groupnot disclosednot disclosednot disclosednot disclosed
Mednax (MD)180%RSU 50 · PSU 50NoSemler Brossy Consulting Group
National HealthCarenot disclosednot disclosednot disclosedfalse
Oak Street Healthnot disclosednot disclosednot disclosednot disclosed
RadNetnot disclosedRSU 100NoPearl Meyer
Surgery Partnersnot disclosedPSU 60 · Restricted Stock 40NoFrederic W. Cook & Co., Inc. (FW Cook)
Teladoc Health73%RSU 50 · PSU 50NoAon
The Ensign Groupnot disclosednot disclosednot disclosedWillis Towers Watson
U.S. Physical Therapynot disclosednot disclosednot disclosedMeridian Compensation Partners, LLC

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20232023-06-15120,520,092329,665,0282,278,19726.77%Failed
20222022-05-16400,342,80713,314,689525,00596.78%Passed
20212021-06-02—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20232023-06-1526.77%a
20222022-05-1696.78%b
20212021-06-02—c

a. Approved under the standard stated in the filing — “The affirmative vote of a majority of the shares of common stock present or represented by proxy at the Annual Meeting and entitled to vote thereon is required to approve this proposal. || Abstentions: Abstentions and broker non-votes will have no effect on the outcome of the non-binding, advisory vote to approve the compensation of our named executive officers.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of the non-binding, advisory vote to approve the compensation of our named executive officers.”.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)114 : 1
CEO total compensation$4,320,007
Median employee compensation$37,916
Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Richard AguilarChief Clinical Officer2023-05-25D600,000$0$0Derivative, Class A CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-05-25D600,00000Derivative, Class A CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-05-25D675,94000Derivative, Class A CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-05-25D675,94000Derivative, Class A CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-05-25A600,00000CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-05-25A675,94000CommonForm 4 ↗
Mark NovellChief Accounting Officer2023-05-31A60,502——RSUForm 4 ↗
David ArmstrongSee remarks2023-05-31A109,526——RSUForm 4 ↗
Marlow HernandezDirector2023-05-31A671,742——RSUForm 4 ↗
Brian KoppyChief Financial Officer2023-05-31A248,226——RSUForm 4 ↗
Richard AguilarChief Clinical Officer2023-05-31A231,008——RSUForm 4 ↗
Robert CamerlinckChief Operating Officer2023-05-31A239,139——RSUForm 4 ↗
David ArmstrongSee remarks2023-06-06D3,16314,351CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-07D400,0001528,400CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-08D275,9401356,156CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-08A600,00000CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-08D600,00000CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-09D100,0001137,760CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-12D500,0001711,650CommonForm 4 ↗
Jacqueline GuichelaarDirector2023-06-15A185,598——CommonForm 4 ↗
Angel MoralesDirector2023-06-15A185,598——CommonForm 4 ↗
Dr. Alan MuneyDirector2023-06-15A185,598——CommonForm 4 ↗
Kim RiveraDirector2023-06-15A185,598——CommonForm 4 ↗
Solomon D. TrujilloDirector2023-06-15A211,581——CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-26D550,00000Derivative, Class A CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-26D550,00000Derivative, Class A CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-26A550,00000CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-28D150,0001183,300CommonForm 4 ↗
Richard AguilarChief Clinical Officer2023-06-29D400,0001525,760CommonForm 4 ↗
David ArmstrongSee remarks2023-06-30A7,50615,780CommonForm 4 ↗
Marlow HernandezDirector2023-07-12A189,681——CommonForm 4 ↗
Mark D. KentInterim CEO2023-07-12A1,138,088——CommonForm 4 ↗
Mark D. KentInterim CEO2023-07-12A216,237——CommonForm 4 ↗
Robert CamerlinckChief Operating Officer2023-08-11D30,646123,453CommonForm 4 ↗
Eladio GilInterim CFO2023-11-10A7,67600RSUForm 4 ↗
Angel MoralesDirector2023-11-20D69,68500Derivative, Class A CommonForm 4 ↗
Angel MoralesDirector2023-11-20D69,68500Derivative, Class A CommonForm 4 ↗
Angel MoralesDirector2023-11-20A69,685——Common, indirectForm 4 ↗
Solomon D. TrujilloDirector2023-12-07A136,804——CommonForm 4 ↗
Solomon D. TrujilloDirector2023-12-07D136,80400Derivative, Class A CommonForm 4 ↗
Solomon D. TrujilloDirector2023-12-07D136,80400Derivative, Class A CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-15D532,60300Derivative, Class A CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-15D532,60300Derivative, Class A CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-15A532,603——CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-21D82,8436469,430CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-21D6,309741,765CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-22D27,3776154,787CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-26D21,1545115,124CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-27D37,6076212,370CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-28D41,1976247,227CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2023-12-29D35,1126210,644CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-02D43,5055235,658CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-03D24,1825119,423CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-03D50,8184207,251CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-04D13,328453,297CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-05D25,000496,233CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-08D25,000495,553CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-09D25,000493,673CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-10D25,000493,293CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-11D25,000489,790CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-12D1,065,20600Derivative, Class A CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-12A1,065,206——CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-12D24,171379,878CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-12D1,065,20600Derivative, Class A CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-17D5,987317,489CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-17D94,0132214,058CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-18D100,0002191,250CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-22D125,0003312,763CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-23D73,0343214,800CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-24D35,8083101,612CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-25D18,569347,960CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-26D32,693389,736CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-29D41,3573113,471CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-30D12,703334,285CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-01-31D8,935323,177CommonForm 4 ↗
Elliot CooperstoneGreater-than-10% holder2024-02-01D1,10032,780CommonForm 4 ↗
Mark D. KentDirector2024-06-28A94,416——Derivative, Class A CommonForm 4 ↗
Eladio GilInterim CFO2024-06-28D7,676——CommonForm 4 ↗
Mark D. KentDirector2024-06-28D1,749——CommonForm 4 ↗
Mark D. KentDirector2024-06-28D23,609——CommonForm 4 ↗
Mark D. KentDirector2024-06-28D23,609——CommonForm 4 ↗
Mark D. KentDirector2024-06-28D45,995——CommonForm 4 ↗
Mark D. KentDirector2024-06-28D15,296——CommonForm 4 ↗
Angel MoralesDirector2024-06-28D2,485——CommonForm 4 ↗
Nut Tree Capital Management, LPGreater-than-10% holder2024-06-28A17,054——Derivative, Class A CommonForm 4 ↗
Nut Tree Capital Management, LPGreater-than-10% holder2024-06-28A347,603——Derivative, Class A CommonForm 4 ↗
Nut Tree Capital Management, LPGreater-than-10% holder2024-06-28A32,750——Derivative, Class A CommonForm 4 ↗
Nut Tree Capital Management, LPGreater-than-10% holder2024-06-28A555,508——Common, indirectForm 4 ↗
Nut Tree Capital Management, LPGreater-than-10% holder2024-06-28A9,557,095——Common, indirectForm 4 ↗
Robert CamerlinckChief Operating Officer2024-06-28D269,586——CommonForm 4 ↗
David ArmstrongSee remarks2024-06-28A6,641——CommonForm 4 ↗
Solomon D. TrujilloDirector2024-06-28D3,782——CommonForm 4 ↗
Solomon D. TrujilloDirector2024-06-28D136,804——CommonForm 4 ↗
Dr. Alan MuneyDirector2024-06-28D2,485——CommonForm 4 ↗
Angel MoralesDirector2024-06-28D69,685——Common, indirectForm 4 ↗
Kim RiveraDirector2024-06-28D2,485——CommonForm 4 ↗
Mark D. KentDirector2024-06-28D1,749——CommonForm 4 ↗
Nut Tree Capital Management, LPGreater-than-10% holder2024-06-28A912,538——Common, indirectForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (143 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Marlow Hernandez. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 4,320,007. View filing ↗
  • Section 01, Robert Camerlinck. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 3,703,685. View filing ↗
  • Section 01, Brian Koppy. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 1,429,945. View filing ↗
  • Section 01, Richard Aguilar. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 1,363,834. View filing ↗
  • Section 01, David Armstrong. DEF 14A, filed 2023-05-22. Section “Executive Compensation Tables” · page 35. As printed: 1,040,551. View filing ↗
  • Section 03, Marlow Hernandez RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, Robert Camerlinck OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, Richard Aguilar RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, Richard Aguilar OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, Marlow Hernandez OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, Robert Camerlinck RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, David Armstrong RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, David Armstrong OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, Robert Camerlinck RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, Brian Koppy RSU. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 03, Brian Koppy OPTION. DEF 14A, filed 2023-05-22. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
  • Section 07, pay ratio. DEF 14A. Section “CEO Pay Ratio”. As printed: 114 : 1.
  • Section 08, Solomon D. Trujillo. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 446,175. View filing ↗
  • Section 08, Elliot Cooperstone. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
  • Section 08, Jacqueline Guichelaar. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
  • Section 08, Dr. Lewis Gold. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
  • Section 08, Angel Morales. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
  • Section 08, Barry S. Sternlicht. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
  • Section 08, Kim Rivera. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
  • Section 08, Dr. Alan Muney. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 376,917. View filing ↗
  • Section 08, Dr. Marlow Hernandez. DEF 14A, filed 2023-05-22. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-05-25. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Novell 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David Armstrong 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Marlow Hernandez 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Brian Koppy 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Robert Camerlinck 2023-05-31. Form 4, filed 2023-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David Armstrong 2023-06-06. Form 4, filed 2023-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-07. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-08. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-08. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-08. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-09. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-12. Form 4, filed 2023-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jacqueline Guichelaar 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Angel Morales 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dr. Alan Muney 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kim Rivera 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Solomon D. Trujillo 2023-06-15. Form 4, filed 2023-06-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-26. Form 4, filed 2023-06-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-26. Form 4, filed 2023-06-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-26. Form 4, filed 2023-06-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-28. Form 4, filed 2023-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard Aguilar 2023-06-29. Form 4, filed 2023-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David Armstrong 2023-06-30. Form 4, filed 2023-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Marlow Hernandez 2023-07-12. Form 4, filed 2023-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark D. Kent 2023-07-12. Form 4, filed 2023-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark D. Kent 2023-07-12. Form 4, filed 2023-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Robert Camerlinck 2023-08-11. Form 4, filed 2023-08-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Eladio Gil 2023-11-10. Form 4, filed 2023-11-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Angel Morales 2023-11-20. Form 4, filed 2023-11-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Angel Morales 2023-11-20. Form 4, filed 2023-11-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Angel Morales 2023-11-20. Form 4, filed 2023-11-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Solomon D. Trujillo 2023-12-07. Form 4, filed 2023-12-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Solomon D. Trujillo 2023-12-07. Form 4, filed 2023-12-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Solomon D. Trujillo 2023-12-07. Form 4, filed 2023-12-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-15. Form 4, filed 2023-12-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-15. Form 4, filed 2023-12-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-15. Form 4, filed 2023-12-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-21. Form 4, filed 2023-12-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-21. Form 4, filed 2023-12-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-22. Form 4, filed 2023-12-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-26. Form 4, filed 2023-12-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-27. Form 4, filed 2023-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-28. Form 4, filed 2023-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2023-12-29. Form 4, filed 2023-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-02. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-03. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-03. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-04. Form 4, filed 2024-01-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-05. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-08. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-09. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-10. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-11. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-12. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-12. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-12. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-12. Form 4, filed 2024-01-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-17. Form 4, filed 2024-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-17. Form 4, filed 2024-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-18. Form 4, filed 2024-01-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-22. Form 4, filed 2024-01-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-23. Form 4, filed 2024-01-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-24. Form 4, filed 2024-01-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-25. Form 4, filed 2024-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-26. Form 4, filed 2024-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-29. Form 4, filed 2024-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-30. Form 4, filed 2024-02-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-01-31. Form 4, filed 2024-02-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elliot Cooperstone 2024-02-01. Form 4, filed 2024-02-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Eladio Gil 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Angel Morales 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Robert Camerlinck 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David Armstrong 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Solomon D. Trujillo 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Solomon D. Trujillo 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dr. Alan Muney 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Angel Morales 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kim Rivera 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark D. Kent 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nut Tree Capital Management, LP 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-22. Item 5.07 · say-on-pay result. As reported: 26.77% (votes for as printed: 120,520,092). View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-05-18. Item 5.07 · say-on-pay result. As reported: 96.78% (votes for as printed: 400,342,807). View filing ↗
  • Section 06, 2021 vote. Form 8-K, filed 2021-06-02. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 425,753 + equity 2,658,841 + all other 0 = 3,084,594, summed across the director compensation table rows.
  • Apollo Medical Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Apollo Medical Holdings's own proxy. As printed: 14,930,231. View filing ↗
  • Mednax (MD), Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Mednax (MD)'s own proxy. As printed: 14,140,217. View filing ↗
  • The Ensign Group, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in The Ensign Group's own proxy. As printed: 13,804,700. View filing ↗
  • Addus HomeCare, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Addus HomeCare's own proxy. As printed: 12,190,449. View filing ↗
  • RadNet, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in RadNet's own proxy. As printed: 12,087,934. View filing ↗
  • Teladoc Health, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Teladoc Health's own proxy. As printed: 11,202,996. View filing ↗
  • Encompass Health, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Encompass Health's own proxy. As printed: 10,297,258. View filing ↗
  • Acadia Healthcare, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Acadia Healthcare's own proxy. As printed: 7,909,463. View filing ↗
  • Surgery Partners, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Surgery Partners's own proxy. As printed: 6,083,862. View filing ↗
  • U.S. Physical Therapy, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in U.S. Physical Therapy's own proxy. As printed: 4,468,314. View filing ↗
  • Cano Health (subject), Section 10b CEO total. DEF 14A, filed 2023-05-22. CEO total compensation as printed in Cano Health's own proxy. As printed: 4,320,007. View filing ↗
  • National HealthCare, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in National HealthCare's own proxy. As printed: 2,685,370. View filing ↗
  • CorVel, Section 10b CEO total. DEF 14A, filed 2026-06-26. CEO total compensation as printed in CorVel's own proxy. As printed: 1,285,043. View filing ↗